|
Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, that manufactures branded and non-branded generic and in-licensed pharmaceutical products. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index. In 2013, Hikma delivered 23% group revenue growth 〔(Hikma Annual Report 2013 page 34 )〕 and is the largest regional pharmaceutical company in the MENA region.〔(【引用サイトリンク】title=Hikma at a glance )〕 It was founded in Amman, Jordan in 1978 by Samih Darwazah. ==History== The Company was founded by Samih Darwazah in 1978 in Amman in Jordan.〔(Hikma History )〕 In August 1996 it became the first Arab company to export pharmaceutical products to the United States.〔(【引用サイトリンク】title=Economy - Sectoral Analysis )〕 It was first listed on the London Stock Exchange in 2005.〔 Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005〔(Hikma Annual Report 2006 Page 62 )〕 and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.〔 In 2007 the Company went on to buy APM in Jordan,〔(Hikma Annual Report 2007 Page 15 )〕 Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia〔 Thymoorgan in Germany〔 and Ribosepharm in Germany.〔 It also acquired Multi-Source Injectables in the USA in October 2010.〔(【引用サイトリンク】title=Garcinia Cambogia Extract Reviews - Is This Super Food The Holy Grail Of Weight Loss? )〕 In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI). In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco. Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.〔(Hikma Pharmaceuticals Inaugurates Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria )〕 In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.〔(【引用サイトリンク】title=Login - Evaluate )〕 Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.〔(【引用サイトリンク】title=Hikma expands in Egypt with EPCI acquisition )〕 In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market 〔(Hikma Annual Report 2013 page 23 )〕 On May 28, 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.〔(【引用サイトリンク】title=Hikma buys Boehringer injectable drugs business for up to $300 mln )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Hikma Pharmaceuticals」の詳細全文を読む スポンサード リンク
|